A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00885963
Recruitment Status : Terminated
First Posted : April 22, 2009
Last Update Posted : February 10, 2014
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc.

March 31, 2009
April 22, 2009
February 10, 2014
December 2008
June 2014   (Final data collection date for primary outcome measure)
the rate of response and stable disease [ Time Frame: after cycle 2, 4, 7 and every 3 cycles thereafter ]
Same as current
Complete list of historical versions of study NCT00885963 on Archive Site
  • progression-free survival [ Time Frame: 1.5 years ]
  • duration of response [ Time Frame: 1.5 years ]
  • duration of stable disease [ Time Frame: 1.5 years ]
  • overall survival [ Time Frame: 1.5 years ]
Same as current
Not Provided
Not Provided
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
This is an open label, single arm, phase II study to evaluate the safety and efficacy of oral sapacitabine administered twice daily for 5 consecutive days every week for 2 weeks followed by 7-day rest in patients who have had one prior chemotherapy regimen for advanced Non-Small Cell Lung Cancer (NSCLC).
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Non-small Cell Lung Cancer
Drug: sapacitabine
twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
Experimental: sapacitabine
Intervention: Drug: sapacitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2014
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed recurrent NSCLC
  • Age of 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Measurable disease according to RECIST
  • Had only 1 prior chemotherapy regimen for metastatic or recurrent disease; patients who have received more than one prior chemotherapy regimens may participate in Part A of the study only.
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate liver function
  • At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy; at least 7 days from prior radiation therapy; and have recovered from prior toxicities
  • At least 3 weeks from major surgery
  • Patient must be able to swallow capsules
  • Agree to practice effective contraception during the entire study period and for one month after being discontinued from the study unless documentation of infertility exists. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

  • NSCLC histology contains a component of small cell lung cancer
  • Previously untreated CNS metastasis or progressive CNS metastasis documented by MRI scan performed at 4 weeks or longer after the last treatment for CNS metastasis
  • Currently receiving radiotherapy, biological therapy, or any other investigational agents
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Cancer other than NSCLC that has been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer, and basal or squamous cell skin cancer; patients who received only hormonal therapy in the neoadjuvant or adjuvant setting in the past 5 years may participate in this study
  • Pregnant or lactating women
  • Known to be HIV-positive
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
Not Provided
Study Chair: Philip Bonomi, M.D. Rush University Medical Center
Cyclacel Pharmaceuticals, Inc.
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP